Chile to India Pharmaceutical Import

The pharmaceutical trade corridor between Chile and India has experienced modest activity from 2022 to 2026. Over this period, India imported a total of $60,000 USD worth of finished pharmaceutical formulations from Chile, distributed across 34 shipments. This equates to an average shipment value of approximately $2,000 USD. The trade involved eight Chilean suppliers and six Indian buyers, indicating a niche yet consistent exchange in the pharmaceutical sector. The predominant product in this trade was paracetamol, accounting for 97.9% of the total import value. Other imported products included lenalidomide, empagliflozin, and amlodipine, among others. The primary Chilean supplier was Pinnacle Chile SPA, which supplied paracetamol in two shipments valued at $59,000 USD. On the Indian side, Pinnacle Life Science Private Limited was the main buyer, importing paracetamol from Chile. This trade corridor, while limited in volume, highlights the specialized nature of pharmaceutical imports from Chile to India.

Chile's contribution to India's pharmaceutical imports is relatively minor. In 2024, India imported pharmaceutical products worth $2.8 billion USD, with imports from Chile amounting to $60,000 USD, representing a fraction of a percent of the total. The imports from Chile were predominantly finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The focus on paracetamol suggests that Chile's pharmaceutical exports to India are concentrated in specific therapeutic areas, catering to particular market needs.

Between 2024 and 2026, there have been no significant policy changes or trade agreements specifically affecting the pharmaceutical import relationship between Chile and India. The Central Drugs Standard Control Organisation (CDSCO) in India has maintained its existing regulatory framework for foreign pharmaceutical imports, ensuring consistent standards for product safety and efficacy. Similarly, Chile's National Drug Regulatory Authority continues to uphold its WHO-GMP standards for pharmaceutical exports. The lack of major developments indicates a stable, albeit limited, trade relationship in the pharmaceutical sector between the two nations.

For Chilean pharmaceutical companies aiming to export finished formulations to India, obtaining registration with the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:

1. Application Submission: Companies must apply through the CDSCO's online portal, providing detailed information about the applicant and the products intended for import.

3. Regulatory Review: CDSCO evaluates the application to ensure compliance with Indian standards. This may involve site inspections and assessments of product safety and efficacy.

4. Approval and Registration: Upon successful evaluation, CDSCO grants approval, allowing the company to export pharmaceutical products to India.

The entire process can take several months, depending on the completeness of the application and the regulatory review timeline. It's crucial for Chilean companies to ensure all documentation is accurate and comprehensive to facilitate a smooth registration process.

India requires that all imported pharmaceutical products adhere to Good Manufacturing Practice (GMP) standards. Chilean manufacturing sites must comply with these standards, which are in line with the World Health Organization's (WHO) GMP guidelines. To demonstrate compliance, Chilean manufacturers should obtain WHO prequalification for their products. Additionally, CDSCO may conduct inspections of foreign manufacturing facilities to verify adherence to GMP standards. Maintaining high-quality manufacturing practices is essential for Chilean companies to ensure their products meet the stringent requirements of the Indian market.

Chilean pharmaceutical companies exporting to India must prepare and submit several key documents to CDSCO:

• Import License (Form 10): This license authorizes the import of pharmaceutical products into India.

• Registration Certificate: Issued by CDSCO, this certificate confirms that the imported products are approved for sale and distribution in India.

• No Objection Certificate (NOC): This certificate is required for certain products, such as blood products, to ensure they meet Indian standards.

• Test License: For products intended for clinical trials or testing, a test license is necessary.

• Customs Documentation: Proper customs procedures must be followed, including the submission of import declarations and payment of applicable duties and taxes.

Ensuring all documentation is accurate and complete is vital for the timely clearance of pharmaceutical imports through Indian customs.

The pharmaceutical imports from Chile to India are predominantly focused on specific therapeutic areas, with paracetamol being the most significant import. This suggests that Chile's pharmaceutical exports to India are concentrated in the analgesic segment, catering to the demand for pain relief medications. The limited variety of imported products indicates that Chile's pharmaceutical offerings in the Indian market are specialized, possibly due to production capabilities or strategic market positioning.

The current trade data indicates that the pharmaceutical imports from Chile to India are limited to standard formulations, with no significant presence of innovator drugs, novel formulations, or advanced therapies. This suggests that Chilean pharmaceutical exports to India may not yet include cutting-edge or specialized products, potentially due to regulatory challenges, market entry barriers, or a focus on more established product lines.

The demand for pharmaceutical imports from Chile to India is likely driven by several factors:

• Patent Protection: Chilean pharmaceutical products may offer patent protection, providing exclusivity in the Indian market.

• Technology Gaps: Certain formulations or manufacturing technologies in Chile may not be available domestically in India, creating a niche market for imports.

• Quality Requirements: Chilean products may meet specific quality standards that align with the preferences of Indian consumers or regulatory bodies.

• Disease Burden: The prevalence of certain health conditions in India may drive the need for specific pharmaceutical products, such as paracetamol for pain management.

These factors collectively contribute to the sustained, albeit limited, demand for pharmaceutical imports from Chile to India.

India's import tariff structure for pharmaceutical formulations includes several components:

• Most Favored Nation (MFN) Tariff Rates: These are the standard import duty rates applied to goods from WTO member countries, including Chile.

• Basic Customs Duty (BCD): This is the primary duty levied on imported goods, calculated as a percentage of the product's value.

• Integrated Goods and Services Tax (IGST): Applied to imported goods, IGST is calculated on the total value of the goods, including customs duties.

• Health Cess: A specific levy imposed on certain imported pharmaceutical products to fund health initiatives.

The exact rates for these duties and taxes can vary and are subject to periodic revisions by the Indian government. Chilean exporters should consult the latest notifications from the Directorate General of Foreign Trade (DGFT) and the Central Board of Indirect Taxes and Customs (CBIC) to determine the applicable rates for their products.

As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Chile concerning pharmaceutical products. The Partial Scope Trade Agreement between India and Chile, signed in 2007 and deepened in 2017, provides tariff preferences ranging from 20 percent to 100 percent for pharmaceutical products. However, the limited volume of pharmaceutical trade between the two countries suggests that these preferences have had a minimal impact on the overall trade dynamics. Both nations continue to engage in bilateral negotiations to explore opportunities for enhancing trade relations, but no significant developments have been reported in the pharmaceutical sector.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by restricting the patentability of new forms of known substances unless they demonstrate enhanced efficacy. This provision can impact the import of certain pharmaceutical products from Chile if they are considered incremental innovations. Additionally, the National Pharmaceutical Pricing Authority (NPPA) in India exercises price control over essential medicines, which can affect the pricing strategies of imported drugs. Chilean pharmaceutical companies must navigate these regulatory frameworks to ensure